Therefore, we decided to study the expression of these three miRNAs and their relation with clinical outcomes (distant metastasis development and death of melanoma) separately in BRAF WT and BRAF mutated primary tumors, in order to detect differences in the miRNAs’ behavior between both groups and to see if miRNAs were able to discriminate properly among primary tumors that will develop metastasis and, among the latter, those that will die of melanoma, in both groups. This evidence concerns the gene BRAF and melanoma.